Jain Global’s Denali Therapeutics DNLI Stock Holding History

Jain Global’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,414	Closed	-$253K	–	1289
2025 Q3	$253K	Buy	17,414 +2,928	+20%	+$42.1K	﹤0.01%	848
2025 Q2	$203K	Buy	+14,486	New	+$204K	﹤0.01%	975

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jain Global's DNLI Position: Q4 2025 in Review

Jain Global sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 17,414 shares — an estimated $253K sold.

Jain Global first reported a position in DNLI in Q2 2025 and held it in 2 quarters. The position peaked at $253K in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Jain Global reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Jain Global sold 17,414 Denali Therapeutics shares in Q4 2025, an estimated $253K.
Jain Global first reported a position in Denali Therapeutics in Q2 2025 and held it in 2 quarters.
Jain Global's Denali Therapeutics position peaked at $253K in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Jain Global's 13F filing for Q4 2025, filed 17 Feb 2026.